Nice to see these precedents being set by FDA for stem cell therapies. Augers well for MSB's aGVHD application.
Also, I didn't realise GILD was fairly active in acquiring cell based therapy companies. They bought out Kite for $11.9B in 2017. Will add GILD to the list of potential acquirers of MSB. They have been under pressure to buy new lines of revenue for the last 7-8 years since their hepatitis cures reached peak sales. I was a holder some time ago.
https://www.gilead.com/news-and-press/press-room/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion
Cell Therapy News/Articles, page-4998
-
- There are more pages in this discussion • 12,794 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |